New cocktail aims to outsmart Drug-Resistant lung cancer
NCT ID NCT04285671
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding two antibody drugs (trastuzumab and necitumumab) to the standard pill osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib alone. About 30 participants will receive the combination to find the best dose and see how well it works. The goal is to overcome drug resistance and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab, necitumumab, and osimertinib
What this could lead to
If it works, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States